Key result
Impella is feasible for cardiogenic shock during TAVR, but 30-day mortality remains ~40%.
Why the study?
Severe aortic stenosis is usually considered a contraindication to Impella implantation, but its role in supporting high-risk PCI or complicated TAVR remains to be clarified.
Is the Impella ventricular assist device feasible and effective for hemodynamic support in patients with severe aortic stenosis undergoing high-risk PCI or complicated TAVR?
Is the Impella ventricular assist device feasible and effective for hemodynamic support in patients with severe aortic stenosis undergoing high-risk PCI or complicated TAVR?
Answers are grounded in this paper and cite their sources.
Despite severe aortic stenosis traditionally being a contraindication, Impella may be a feasible option for hemodynamic support during pre-TAVR high-risk PCI or for cardiogenic shock complicating TAVR.
Key Points Severe aortic stenosis is usually considered a contraindication to the implantation of Impella ventricular assist device. In the setting of pre‐transcatheter aortic valve replacement (TAVR), high‐risk percutaneous coronary intervention, Impella stabilizes hemodynamics by reducing left ventricular end‐diastolic pressure and increasing cardiac output and coronary perfusion. The implantation of Impella was feasible for the treatment of cardiogenic shock occurring during TAVR. Nevertheless, 30‐day mortality remained as high as 40%.
No takes yet. Share an insight, caveat, or question.
Tarantini et al. (2020) conducted a review in Severe aortic stenosis, high-risk percutaneous coronary intervention, or cardiogenic shock during TAVR. Impella ventricular assist device was evaluated on 30-day mortality. Impella implantation was feasible for treating cardiogenic shock during TAVR, although 30-day mortality remained as high as 40%.
Synapse has enriched 10 related papers. Consider them for comparative context: